

# Daily Program Schedule

## Wednesday, September 27

P In Person    D On-Demand    V Virtual

08:00 - 08:30	<b>PRESIDENT'S ADDRESS</b> <span>P</span> <span>V</span> <span>D</span>	Nikhil Munshi	Trianti
08:30 - 09:00	<b>KEYNOTE</b> <span>P</span> <span>D</span> Somatic mutations in normal tissues	Peter Campbell	Trianti
09:00 - 14:30	<b>EXHIBITION OPEN</b>		Muses Foyer
09:00 - 09:15	<b>EXHIBITION AND COFFEE BREAK</b>		Muses Foyer
09:15 - 11:15	<b>ORIGIN OF MM CELLS</b> <span>P</span> <span>V</span> <span>D</span> <i>Chair: Nikhil Munshi, Co-Chair: Faith Davies</i> Charting the genetic evolution in myeloma cell Novel in vivo models of myeloma origin Failure of immune surveillance and disease evolution Is there a role for screening in monoclonal gammopathies? OA-17: Tracking the earliest genomic events in multiple myeloma life-history OA-33: Aberrant B cell differentiation induce plasma cell malignancy OA-25: MM B cells and pre-plasma cell progenitors are the cellular origin of MM disease relapse following effective therapy targeting plasma cells Discuss abstracts in context Round Table discussion	Faith Davies Karin Vanderkerken Madhav Dhodapkar Sigurdur Kristinsson Anthony Cirrincione Wen Zhou Rodger Tiedemann Leif Bergsagel Rafael Fonseca, Andrew Spencer, Rodger Tiedemann, Marta Chesi	Trianti
11:15 - 11:30	<b>EXHIBITION AND COFFEE BREAK</b>		Muses Foyer



11:30 - 13:00

**INDUSTRY SYMPOSIUM SUPPORTED  
BY BRISTOL MYERS SQUIBB** **P V D**

Trianti

**Harnessing the Immune System Before and After CAR T Cell Therapies**

Welcome and Introduction	Hermann Einsele
Update on CAR T cell therapy development	Hermann Einsele
Managing CAR T cell therapies in the real world	Yi Lin
Immune Profiling and Cellular Therapies	Bruno Paiva
Immune-Based Strategies for Improving Outcomes	Rakesh Popat
Audience Q&A	Rakesh Popat

13:00 - 14:30

**EXHIBITION AND LUNCH**

Muses Foyer and Courtyard

13:30 - 14:30

**POSTER SESSION 1** **P**

Trianti Upper Foyer

14:30 - 16:30

**NEWLY DIAGNOSED  
MULTIPLE MYELOMA** **P V D**

Trianti

*Chair: Maria-Victoria Mateos, Co-Chair: Vincent Rajkumar*

What is the optimal upfront therapy - 3 or 4 drugs? Saad Usmani

Who needs an autologous stem cell transplant upfront? Aurore Perrot

What is the ideal duration of treatment: MRD-guided or until progression? Kwee Yong

Optimizing supportive care management Evangelos Terpos

OA-10: Four years treatment with Zoledronic Acid is superior to two years in protection against progressive bone disease in Multiple Myeloma Thomas Lund

OA-43: Analysis of sustained MRD-negativity and Progression-free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma – Additional Data from Planned Interim Analysis of the GMMG-CONCEPT Trial Lisa Leypoldt

OA-14: Persistent bone marrow and imaging MRD negativity may guide the duration of lenalidomide maintenance following ASCT in patients with multiple myeloma Panagiotis Malandrakis

Discuss abstracts in context and unmet needs Vincent Rajkumar

Round Table discussion Michele Cavo, Sergio Giralt, Thierry Facon, Jean-Luc Harousseau, Vania Hungria, Bindu Kanapuru

16:30 - 16:45

**COFFEE BREAK**

Muses Foyer



16:45 - 17:45

**ABSTRACT SESSION 1:  
MRD AND RISK STRATIFICATION** **P** **D**

Skalkotas

*Co-Chairs: Morie Gertz and Hartmut Goldschmidt*

OA-12: Predictors of unsustained measurable residual disease (MRD) negativity in transplant-eligible multiple myeloma (MM) patients Camila Guerrero

OA-37: Optimization of the 20/2/20 risk stratification model for patients with smoldering multiple myeloma through integration of the evolving patterns of monoclonal protein and serum free light chains Annika Werly

OA-31: Efficacy of Bispecific Antibodies in the Treatment of Extramedullary disease and High risk cytogenetics in Relapsed Multiple Myeloma: A Systematic Review Charan Vegivinti

OA-38: Physical activity interventions to improve functional performance in patients with multiple myeloma Jens Hillengass

OA-49: Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial Albert Oriol

16:45 - 17:45

**ABSTRACT SESSION 2: BIOLOGY** **P** **D**

Mitropoulos

*Co-Chairs: Annemeik Broji and Lugui Qiu*

OA-35: High-throughput plasma proteomics to define the precursor multiple myeloma proteome and identify candidate high-risk disease biomarkers of progression Elizabeth Lightbody

OA-21: Dysregulated APOBEC3B promotes cell proliferation and DNA damage in multiple myeloma Afsaneh Panahi

OA-36: sBCMA predicts progression and is a biomarker of response in myeloma precursor disease followed on prospective studies wei tan

OA-15: Serial MRD Assessments as a Surrogate for Long Term Progression Free Survival Frits van Rhee

OA-30: Critical roles of CRIP1 in promoting cell survival and bortezomib resistance by enhancing proteasome activity and autophagy in multiple myeloma Hao Mu

17:45 - 18:30

**FIRESIDE CHAT** **P** **D**

Trianti

*Siddhartha Mukherjee/Sagar Lonial/Vincent Rajkumar*

18:30 - 19:45

**EXHIBITION OPEN**

Muses Foyer

18:30 - 19:45

**WELCOME TO ATHENS RECEPTION**

Muses Foyer and Courtyard



# Thursday, September 28

07:00 - 08:00	<b>MEET THE PROFESSOR</b> <span>P</span>	
MR1	Understanding the concept of MGRS	Nelson Leung
MR2	Optimal imaging approaches in MM	Elena Zamagni and Jens Hillengass
MC2	Management of bone disease	Andrew Yee
MC3	Light Chain Amyloidosis	Vaishali Sanchorawala and Ashutosh Wechalekar
MC3.2	Racial disparity: impact and solutions	Lalit Kumar and Craig Cole
MC3.3	Clonal hematopoiesis in myeloma: Implications for therapy	Enrique Ocio and Adam Sperling
MC3.4	Managing Renal Failure in MM	Efstathios Kastritis and Pankaj Malhorta
07:00 - 08:00	<b>CAREER DEVELOPMENT WORKSHOP</b> <span>P</span>	
Skalkotas	Nuts and bolts of developing a clinical trial	Marc Raab and Charlotte Pawlyn
08:00 - 09:00	<b>EHA-IMS SYMPOSIUM</b> <span>P</span> <span>D</span>	Trianti
	<i>Co-Chairs: Pieter Sonnevled and Nikhil Munshi</i>	
	MRD and CLL	Paolo Ghia
	AML and MRD	Jacqueline Cloos
	Regulatory Perspective on MRD in hematological malignancies	Nicole Gormley
09:00 - 10:00	<b>IMS AWARDS</b> <span>P</span> <span>V</span> <span>D</span>	Trianti
10:00 - 13:30	<b>EXHIBITION OPEN</b>	Muses Foyer
10:00 - 10:15	<b>EXHIBITION AND COFFEE BREAK</b>	Muses Foyer



10:15 - 12:15

## NOVEL TECHNOLOGY AND

### INSIGHTS OF MM

Trianti

*Chair: Kenneth Anderson, Co-Chair: Gareth Morgan*

Single cell approach to defining mechanisms of progression for SMM to MM	Irene Ghobrial
Metabolomic alterations defining disease progression in myeloma	Mala Shanmugam
Epigenetic drivers of disease progression	Felipe Prosper
Defining the myeloma cell proteome	Arun Wiita
OA-04: Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma	Maximilian Merz
OA-01: Exploiting microbiota commensals to potentiate immunotherapy and delay multiple myeloma evolution	Laura Lucia Cogrossi
OA-22: TiMMing: Developing an Innovative Suite of Bioinformatic Tools to Harmonize and Track the Origin of Copy Number Alterations in the Evolutionary History of Multiple Myeloma	Andrea Poletti
Discuss abstracts in context	Gareth Morgan
Round Table discussion	Sonja Zweegman, Herve Avet-Loiseau, Wilson Gonsalves, Jill Corre

12:15 - 13:30

## EXHIBITION AND LUNCH

Muses Foyer and Courtyard

12:30 - 13:30

## POSTER SESSION 2

Trianti Upper Foyer

13:30 - 15:00

## INDUSTRY SYMPOSIUM SUPPORTED BY JANSSEN

Trianti

### A new frontier? Redirecting treatment strategies in MM

*Chair: Michel Delforge*

Time to combine? Evolving treatment options in NDMM	Leo Rasche
Time to tailor? Treatment selection at first relapse and beyond	Michel Delforge
Time for T? Expanding treatment paradigms in the later-line RR setting	Roberto Mina
Panel discussion and meeting close	



15:00 - 17:00

**TRIPLE CLASS REFRACTORY MYELOMA** **P** **V** **D**

Trianti

*Chair: Philippe Moreau, Co-Chair: Sagar Lonial*

How should we define refractoriness in myeloma?	Nizar Bahlis
Molecular determinants of drug resistance	Lawrence Boise
Role of tumor microenvironment in drug resistance	Suzanne Lentzsch
Non-Immune therapy for TCR	Paula Rodriguez-Otero
OA-06: Robust in vivo expansion and long-term persistence of anti-BCMA CAR T cells, PHE885, manufactured in < 2 days on the T-Charge platform	Shuntaro Ikegawa
OA-23: Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis	Alexandra Poos
OA-24: Sequential and persistent loss of BCMA and GPRC5D after bispecific antibodies in multiple myeloma revealed by whole genome sequencing	Leo Rasche
Discuss abstracts in context	Sagar Lonial
Round Table discussion	Ajai Chari, P. Joy Ho, Keith Stewart, Meletios Dimopoulos, Donna Reece, Bindu Kanapuru

17:00 - 17:15

**COFFEE BREAK**

Muses Foyer

17:15 - 18:15

**ABSTRACT SESSION 3: NOVEL COMBINATIONS, ACCESS AND LONG TERM OUTCOMES** **P** **D**

Skalkotas

*Co-Chairs: Gordon Cook and Eirini Katodritou*

OA-41: Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial	Darrell White
OA-29: First Results From the Randomized Portion of a Phase 2 Study of Venetoclax Plus Carfilzomib-Dexamethasone vs Carfilzomib-Dexamethasone in Patients With t(11;14) Relapsed/Refractory Multiple Myeloma	Jonathan Kaufman
OA-44: Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial	Meral Beksac
OA-42: Second Primary Malignancies after Tandem Autologous Hematopoietic Stem Cell Transplantation for patients with Multiple Myeloma Treated on Earlier Total Therapy Protocols	Samer Al Hadidi
OA-54: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with tandem transplant in high-risk newly diagnosed myeloma patients: final results of the phase 2 study IFM 2018-04	Cyrille Touzeau



17:15 - 18:15

**ABSTRACT SESSION 4: GENOMICS** **P** **D**

Mitropoulos

*Co-Chairs: Mark Bustoros and Masood Shammas*

OA-19: Comprehensive genomic characterization of response and resistance to daratumumab- based quadruplet induction in newly diagnosed multiple myeloma patients

Kylee Maclachlan

OA-16: The rs9344 G risk allele upregulates CCND1 expression through t(11;14) and PAX5 in multiple myeloma

Linda Baughn

OA-46: Epigenetic regulation of CD38/48 by KDM6A mediates NK cell response in multiple myeloma

Jiye Liu

OA-28: Unraveling the heterogeneity of multiple myeloma associated with therapy resistance by single-cell RNA sequencing

Takahiro Kamiya

OA-18: Identification of therapy-induced clonal evolution and resistance pathways in MRD clones in multiple myeloma through single-cell sequencing

Jian Cui

19:00 - 22:00

**IMS CULTURAL CELEBRATION**

Ble Azure

## Friday, September 29

07:00 - 08:00

**MEET THE PROFESSOR** **P**

MR1

Approaches to MRD assessment

Ajay Nooka and Suzanne Trudel

MR2

Waldenström Macroglobulinemia

Prashant Kapoor and Veronica Leblond

MC2

Assessing QOL and PRO measures

Tanya Wilde and Raphael Szalat

MC3

Laboratory assessment of immune function

David Avigan and Heinz Ludwig

MC3.2

Single cell genomic techniques for study of myeloma

Samir Parekh and Brian Walker

MC3.3

Proteomic evaluation in MM

Constantine Mitsiades and Manoj Bhasin

MC3.4

Optimizing in vitro cellular models of MM

Mariateresa Fulciniti and Niccolo Bolli

07:00 - 08:00

**CAREER DEVELOPMENT WORKSHOP** **P**

Skalkotas

Setting up your laboratory research program

Paola Neri and Mehmet Samur



08:00 - 09:00

## RINEY SESSION P D

Trianti

*Co-Chairs: Kenneth Anderson and Nikhil Munshi*

Liquid biopsy in myeloma to inform outcome and treatment decisions Jens Lohr

Molecular characterization and therapeutic targeting of protein kinase D2 in T(414) multiple myeloma Raphael Szalat

PNC-27: A Novel Effective Strategy for Targeting the Achilles' Heel of Multiple Myeloma Flavia Pichiorri

Deciphering the human plasma cell niche and its transformation in multiple myeloma by highly multiplexed tissue imaging Marc-A. Baertsch

09:00 - 09:30

## YOUNG INVESTIGATOR AWARDS P

Trianti

09:30 - 14:15

## EXHIBITION OPEN

Muses Foyer

09:30 - 09:45

## EXHIBITION AND COFFEE BREAK

Muses Foyer

09:45 - 11:45

## PRACTICAL ASPECTS P V D OF IMMUNOTHERAPY

Trianti

*Chair: Jesus San Miguel, Co-Chair: Noopur Raje*

Integrating T cell redirection in frontline MM Adam Cohen

How do we sequence CART, Bispecifics and ADC and other drugs? Niels van de Donk

Managing acute Immunotherapy complications Krina Patel

Prevention and monitoring of infections with immunotherapies Joshua Richter

OA-07: Phase I Study of BCMA CAR-T Using Instant Manufacturing Platform or Traditional Production Process for Relapsed/Refractory Multiple Myeloma Therapy Hui Liu

OA-11: Utility of 18FDG-PET/CT for Risk Prediction in Relapsed/Refractory Multiple Myeloma Patients Luis-Esteban Tamariz-Amador

Undergoing CAR-T Cell Therapy: Analysis of Baseline and Early Assessment Scans After One and Three Months

OA-51: Preliminary Recommendations for Prevention and Management of Infections, Hypogammaglobulinemia, and Neutropenia During Treatment With Teclistamab Based on Experience From the MajesTEC-1 Study Niels van de Donk

Discuss abstracts in context Noopur Raje

Round Table discussion Jesus Berdaja, Ivan Borrello, Monika Engelhardt, Sham Mailankody, Tom Martin



**Current Issues in Multiple Myeloma: Management of the Aging Population**
*Chair: Paul Richardson*

Increasing heterogeneity of the aging MM patient population: diagnostic challenges

Alessandra Larocca

Aging of the general population and its impact on MM treatment

Yael Cohen

Treatment options for elderly patients in early RRMM: Immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies

Paul Richardson

BCMA-targeted treatment options for elderly patients in early RRMM

Hang Quach

Roundtable discussion: Practical considerations: eligibility, access and benefit/risk

All speakers

Audience Q&A

Closing remarks

12:45 - 14:15

**EXHIBITION AND LUNCH**

Muses Foyer and Courtyard

13:15 - 14:15

**POSTER SESSION 3** **P**

Trianti Upper Foyer

14:15 - 16:15

**PLENARY SESSION** **P** **V** **D**

Trianti

*Co-Chairs: Bob Orlowski and Qing Yi*

OA-20: Genomic profiling of high-risk smoldering myeloma patients treated with a curative strategy: a biological study of the phase II GEM CESAR clinical trial.

Alejandro Medina-Herrera

Summarize Abstract

Samir Parekh

OA-27: Single cell transcriptomics reveals the impact of tumor cell interactions with the bone marrow immune microenvironment in the progression of multiple myeloma

Parvathi Sudha

Summarize Abstract

Paola Neri

OA-45: Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial

Carlos Fernandez de Larrea

Summarize Abstract

Tom Martin

OA-48: Isatuximab plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (IKEMA): Final Overall Survival Analysis

Philippe Moreau

Summarize Abstract

Sagar Lonial

OA-52: Results From the Randomized, Open-Label Phase 3 CANOVA Study of Venetoclax Versus Pomalidomide Added to Dexamethasone in Patients With t(11;14)-Positive Relapsed/Refractory Multiple Myeloma

Maria-Victoria Mateos

Summarize Abstract

Faith Davies



OA-53: Peripheral Blood and Bone Marrow Residual Disease Negativity to Identify a Subgroup of Newly Diagnosed Multiple Myeloma Patients with Long Term Disease Control

Noemi Puig

Summarize Abstract

Kenneth Anderson

16:15 - 16:30

## COFFEE BREAK

Muses Foyer

16:30 - 17:30

## ABSTRACT SESSION 5: IMMUNE THERAPIES P D

Skalkotas

*Co-Chairs: Simon Harrison and Katja Weisel*

OA-05: Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient- and disease-related factors associated with responses

Simon Harrison

OA-55: Real world experience of patients treated with teclistamab: a BCMA-directed bispecific t-cell engaging therapy for multiple myeloma

Shonali Midha

OA-47: Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PvD or DPd) in lenalidomide-refractory patients with multiple myeloma and 1-3 prior lines of therapy

Salomon Manier

OA-08: GPRC5D-Targeted CAR-T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma Progressing after or Refractory to BCMA CAR-T cell therapy: Updated Results from a Phase 2 Clinical Trial

Jieyun Xia

OA-34: Feasibility of a novel academic anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory AL amyloidosis

Eyal Lebel

16:30 - 17:30

## ABSTRACT SESSION 6: IMMUNE P D

Mitropoulas

*Co-Chairs: Eileen Boyle and Fanghuang Zhan*

OA-32: The Impact of Genomics to Identify Novel Immunotherapeutic Targets in Multiple Myeloma

Brian Walker

OA-02:  $\alpha$ -NKG2A blockade overcomes multiple myeloma resistance to BCMA and NKG2D CAR-NKAE cells

Jessica Encinas Mayoral

OA-09: Combination of forimtamig with standard of care improves depth and duration of response in preclinical models of multiple myeloma

Aintzane Zabaleta

OA-26: Single-cell analysis reveals disease induced perturbations of monocytes in the bone marrow and peripheral blood of multiple myeloma patients

Jian Cui

OA-03: Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma

Ross Firestone



# Saturday, September 30

08:00 - 09:00	<b>MEET THE PROFESSOR</b> <span>P</span>	
MR1	Risk stratified follow up of MGUS and SMM	Meral Beksac and Natalie Callander
MR2	Vaccination and infection prevention	Kartik Ramasamy and Dorotea Fantl
MC2	Solitary tumor plasmacytoma	Carlos Fernandez de Larrea and Andrzej Jakubowiak
MC3	Diagnostic approach to a monoclonal protein (lab-based)	Dave Murray and Joan Bladé
MC3.2	Neuropathy and MGUS	Jorge Castillo and Andrew Branagan
MC3.3	Castleman's and POEMS	Angela Dispenzieri and Frits van Rhee
MC3.4	Artificial Intelligence in Myeloma: what would its utility be?	Marta Sonia González and Claudio Cerchione
08:00 - 09:00	<b>CAREER DEVELOPMENT WORKSHOP</b> <span>P</span>	
Skalkotas	The art of writing grants	Jens Lohr and Mattia D'Agostino
09:00 - 09:40	<b>SPECIAL SESSION</b> <span>P</span> <span>D</span>	Trianti
	<i>Co-Chairs: Meletios Dimopoulos and Efstathios Kastritis</i>	
	Waldenström Macroglobulinemia	Steven Treon
	Amyloidosis	Vaishali Sanchorawala
09:40 - 10:00	<b>COFFEE BREAK</b>	Muses Foyer
10:00 - 11:00	<b>INDUSTRY SYMPOSIUM SUPPORTED BY SANOFI</b> <span>P</span> <span>V</span> <span>D</span>	Trianti
	<b>Monoclonal Antibody based therapies</b>	
	<i>Chair: Joseph Mikhael</i>	
	Welcome and intro: Importance of an individualised approach to achieve the best outcomes	Joseph Mikhael
	Individualizing frontline treatment to get the best outcomes	Xavier Leleu
	Patient cases - RRMM	Elizabeth O'Donnell
	Personalizing treatment approaches beyond frontline	Fredrik Schjesvold
	Audience Q&A	
11:00 - 11:15	<b>COFFEE BREAK</b>	Muses Foyer



11:15 - 13:15

**CHALLENGES IN MM** **P** **V** **D**

Trianti

*Chair: Shaji Kumar, Co-Chair: Francesca Gay*

Defining high-risk and ultra-high risk MM Martin Kaiser

Molecular drivers of extramedullary progression Moritz Binder

Management of EMD and plasma cell leukemia Laura Rosiñol

Managing the older, frail patient with multiple co-morbidities Salomon Manier

OA-13: Increased levels of circulating tumor cells correlate with adverse clinical outcomes and distinct biological features in newly diagnosed patients with multiple myeloma Ioannis Kostopoulos

OA-40: Frailty and initial treatment intensity in patients newly diagnosed with multiple myeloma Clark DuMontier

OA-39: Development and Validation of a Prognostic Survival Model with Patient Reported Outcomes for Older Adults with Multiple Myeloma Hira Mian

Discuss abstracts in context Francesca Gay

Round Table discussion Wee Joo Chng, Cristina Gasparetto, Sundar Jagannath, Hira Mian, Mohamad Mohty

13:15 - 13:30

**CLOSING CEREMONY** **P** **D**

Trianti

13:45 - 14:45

**SPECIAL CAREER** **P** **D**  
**DEVELOPMENT SESSION**

Skalkotas

*Panelists: Suzanne Lentzsch, Andrew Branagan, Ravi Vij*



The IMS gratefully acknowledges the following  
organizations for their sponsorship of the  
20th IMS Annual Meeting:

TITANIUM LEVEL



PLATINUM LEVEL



GOLD LEVEL



BRONZE LEVEL

